Business Context and Reporting Period
This Form 6-K filing by Alcon, Inc. covers the month of December 2002. Alcon is described as the world's leading eye care company, developing, manufacturing, and marketing pharmaceuticals, surgical equipment, devices, and contact lens care solutions. The filing primarily incorporates a news release dated December 5, 2002, regarding a change in the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance news and does not contain financial performance data.
Material Changes
The material change reported is the resignation of Dr. James I. Cash from the Board of Directors, effective December 31, 2002. Dr. Cash had served on the board since the company's initial public offering in March 2002. He cited increased demands on his time, including his role as Senior Associate Dean at Harvard University and his service on the board of Microsoft Corporation, as the reason for his departure.
Guidance, Outlook, and Risks
Alcon intends to nominate a replacement for Dr. Cash at its annual general meeting of shareholders in May 2003. The filing includes a standard caution concerning forward-looking statements, noting that actual results may differ materially from expectations due to known and unknown risks. No specific financial guidance or operational outlook was provided in this document.
Key Facts for Investor Verification
- Dr. James I. Cash resigned from the Alcon Board effective December 31, 2002.
- A replacement director is expected to be nominated at the May 2003 annual general meeting.
- This filing contains no financial results or operational metrics for the period.
- Alcon continues to operate as a global leader in the ophthalmic industry.